{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "hmdb:HMDB06564",
      "entity_text" : "glucose",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:O14842",
      "entity_text" : "GPR40",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Recent phase I and phase II clinical trials in humans have shown that the GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose and lowers HbA 1c with efficacy equal to that of the sulfonylurea glimepiride without inducing hypoglycemia or evidence of tachyphylaxis.",
  "reading_complete" : "2020-07-28T12:10:24Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T12:09:27Z",
  "trigger" : "reduces",
  "evidence" : [ "GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose" ],
  "pmc_id" : "3920793",
  "score" : 0
}